当前位置: 首页 > 期刊 > 《医学信息》 > 2016年第8期
编号:12768919
HE4与ROMA在卵巢癌诊治中的研究分析(3)
http://www.100md.com 2016年2月26日 医学信息 2016年第8期
     [8]Plebani M,Melichar B.ROMA or death:advances in epithelial ovarian cancer diagnosis[J].Clin Chem Lab Med,2011,49(43):3-5.

    [9]Moore,Auranen A,Dean K,et al.Serum HE4 profile during primary of epithelial ovarian cancer[J].Gynecol Cancer, 2011,21(15):73-78.

    [10]Moore R G,Miller M C,Eklund E E,et al.Serum levelsof the ovarian cancer biomarker HE4 are decreased inpregnancy and increase with age[J].Obstet Gynecol,2012,206(4):349-357.

    [11]Moore RG,Brown AK,Miller MC,et al.Utility of a novel serum tumor biomarker HE4 patients with endometrioid of the uterus[J].Gynecol Oncol,2008,110(2):196-201.

    [12]Moore RG,McMeekin DS,Brown AK,et al.A novel multiple marker utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J].Gynecol Oncol,2009,11(2):40-46.

    [13]Ruggieri G,Bandiera E,Zanotti L,et al.HE4 and epithelial ovarian cancer:comparison and clinical evaluation of two immunoassays and a combination algorithm[J].Clin Chim Acta,2011,412(14):47-53.

    [14]Li J,Chen H,Mariani A,et al.HE4(WFDC2)promotes tumour growth in endo-metrial cancer cell lines[J].Mol Sci,2013,14(60)26-43.

    编辑/翟辰万, 百拇医药(高景阳 黄淑华)
上一页1 2 3